for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MacroGenics Inc

MGNX.OQ

Latest Trade

11.00USD

Change

-0.45(-3.93%)

Volume

230,657

Today's Range

10.93

 - 

11.45

52 Week Range

9.87

 - 

32.32

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Macrogenics Inc Reports Quarterly Loss Per Share of $0.65

July 31 (Reuters) - MacroGenics Inc <MGNX.O>::MACROGENICS PROVIDES UPDATE ON CORPORATE PROGRESS AND SECOND QUARTER 2019 FINANCIAL RESULTS.MACROGENICS INC QTRLY TOTAL REVENUE WAS $10.6 MILLION COMPARED TO $18.8 MILLION.MACROGENICS INC - QTRLY LOSS PER SHARE $0.65.MACROGENICS INC - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2019 WERE $272.1 MILLION, COMPARED TO $232.9 MILLION AS OF DECEMBER 31, 2018.MACROGENICS INC - IN SECOND HALF OF YEAR, CO PLANNING TO SUBMIT BLA FOR MARGETUXIMAB.MACROGENICS INC - IN SECOND HALF OF YEAR, CO TO INITIATE TWO REGISTRATION-DIRECTED PHASE 2/3 CLINICAL TRIALS.

MacroGenics Provides Update On Flotetuzumab Program In Acute Myeloid Leukemia

July 17 (Reuters) - MacroGenics Inc <MGNX.O>::MACROGENICS PROVIDES UPDATE ON FLOTETUZUMAB PROGRAM IN ACUTE MYELOID LEUKEMIA.MACROGENICS INC - END OF PHASE 1 MEETING REQUESTED WITH FDA TO DISCUSS PROGRAM AND FUTURE DEVELOPMENT PLANS.MACROGENICS INC - ENROLLMENT OF PHASE 1 MONOTHERAPY EXPANSION COHORT COMPLETED; PRESENTATION OF DATA EXPECTED 2H2019.MACROGENICS INC - INITIATION OF ENROLLMENT OF COMBINATION STUDY WITH ANTI-PD-1 IS IMMINENT.MACROGENICS INC - WILL REGAIN FULL GLOBAL RIGHTS TO FLOTETUZUMAB IN CONNECTION WITH SERVIER'S TERMINATION OF LICENSE AND COLLABORATION AGREEMENT.

Macrogenics And I-Mab Announce Deal To Develop And Commercialize Enoblituzumab In Greater China

July 10 (Reuters) - I-Mab Biopharma: :MACROGENICS AND I-MAB ANNOUNCE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE ENOBLITUZUMAB IN GREATER CHINA.MACROGENICS INC - EXPECTS TO RECEIVE AN UPFRONT PAYMENT OF $15 MILLION IN CONNECTION WITH COLLABORATION.MACROGENICS INC - I-MAB WILL BOTH LEAD REGIONAL STUDIES IN ITS TERRITORIES AS WELL AS PARTICIPATE IN GLOBAL STUDIES CONDUCTED BY MACROGENICS.MACROGENICS INC - WILL BE ELIGIBLE TO RECEIVE ADDITIONAL DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS OF UP TO $135 MILLION.MACROGENICS - INTENDS TO INITIATE PHASE 2 STUDY OF ENOBLITUZUMAB IN COMBINATION WITH MGA012 IN 1ST-LINE PATIENTS WITH HEAD & NECK CANCER LATER THIS YEAR.

Macrogenics Says Public Offering Of 5.50 Mln Common Shares Priced At $20 Per Share

Feb 12 (Reuters) - MacroGenics Inc <MGNX.O>::MACROGENICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $20.00PER SHARE.

MacroGenics Announces Proposed Public Offering Of Common Stock

Feb 12 (Reuters) - MacroGenics Inc <MGNX.O>::MACROGENICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.

MacroGenics Announces Removal Of Partial Clinical Hold On MGD009 Program By FDA

Jan 25 (Reuters) - MacroGenics Inc <MGNX.O>::MACROGENICS ANNOUNCES REMOVAL OF PARTIAL CLINICAL HOLD ON MGD009 PROGRAM BY FDA.MACROGENICS INC - DURING PARTIAL HOLD, COMPLETED ENROLLMENT OF FIRST DOSE ESCALATION COHORT FOR MGC018, OUR B7-H3-TARGETED ADC.MACROGENICS - ENROLLMENT OF NEW PATIENTS IN U.S. HAS BEEN CLEARED TO PROCEED WITH PHASE 1 MONOTHERAPY AND COMBINATION STUDIES OF MGD009.MACROGENICS INC - THE PARTIAL CLINICAL HOLD DID NOT INVOLVE OTHER B7-H3 PROGRAMS.

Macrogenics announces partial clinical hold on mgd009 phase 1 studies

Dec 7 (Reuters) - MacroGenics Inc <MGNX.O>::MACROGENICS ANNOUNCES PARTIAL CLINICAL HOLD ON MGD009 PHASE 1 STUDIES.MACROGENICS INC - PARTIAL CLINICAL HOLD DOES NOT IMPACT ONGOING CLINICAL STUDIES FOR ENOBLITUZUMAB AND MGC018, OTHER B7-H3-TARGETED MOLECULES.".MACROGENICS INC - ON DEC 6, RECEIVED LETTER FROM U.S. FDA INDICATING PARTIAL CLINICAL HOLD HAS BEEN PLACED ON ITS PHASE 1 MONOTHERAPY STUDY OF MGD009.

Trianni, Inc. And Macrogenics, Inc. Announce License Agreement

Dec 6 (Reuters) - MacroGenics Inc <MGNX.O>::TRIANNI, INC. AND MACROGENICS, INC. ANNOUNCE LICENSE AGREEMENT.MACROGENICS INC - NO FINANCIAL DETAILS WERE DISCLOSED..MACROGENICS INC - NO FINANCIAL DETAILS WERE DISCLOSED.

Macrogenics And Zai Lab Announce Agreement To Develop And Commercialize Margetuximab, MGD013 And TRIDENT Molecule In Greater China

Nov 29 (Reuters) - MacroGenics Inc <MGNX.O>::MACROGENICS AND ZAI LAB ANNOUNCE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE MARGETUXIMAB, MGD013 AND TRIDENT™ MOLECULE IN GREATER CHINA.MACROGENICS INC - MACROGENICS TO RECEIVE $25 MILLION UPFRONT CASH PAYMENT AND POTENTIAL FUTURE MILESTONES AND ROYALTIES.MACROGENICS INC - MACROGENICS WILL BE ELIGIBLE TO RECEIVE UP TO $140 MILLION IN POTENTIAL DEVELOPMENT AND REGULATORY-BASED MILESTONE PAYMENTS.MACROGENICS INC - ZAI LAB WOULD PAY MACROGENICS DOUBLE-DIGIT ROYALTIES ON ANNUAL NET SALES OF ASSETS.

NanoString Technologies Says Enters Translational Research Collaboration With MacroGenics To Identify And Develop Biomarkers In Immuno-Oncology

Oct 29 (Reuters) - MacroGenics Inc <MGNX.O>::MACROGENICS AND NANOSTRING ENTER TRANSLATIONAL RESEARCH COLLABORATION TO IDENTIFY AND DEVELOP BIOMARKERS IN IMMUNO-ONCOLOGY.NANOSTRING TECHNOLOGIES INC - CO, MACROGENICS ENTERED AGREEMENT TO IDENTIFY AND DEVELOP BIOMARKERS FOR MACROGENICS' MGD013 PROGRAM.NANOSTRING TECHNOLOGIES INC - WILL DEVELOP, EVALUATE TUMOR INFLAMMATION SIGNATURE AND NOVEL PREDICTIVE GENE EXPRESSION SIGNATURES FOR MGD013.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up